BRPI0506793A - métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5 - Google Patents

métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5

Info

Publication number
BRPI0506793A
BRPI0506793A BRPI0506793-6A BRPI0506793A BRPI0506793A BR PI0506793 A BRPI0506793 A BR PI0506793A BR PI0506793 A BRPI0506793 A BR PI0506793A BR PI0506793 A BRPI0506793 A BR PI0506793A
Authority
BR
Brazil
Prior art keywords
obesity
treatment methods
diabetes treatment
polypeptide
relates
Prior art date
Application number
BRPI0506793-6A
Other languages
English (en)
Inventor
Arnon Rosenthal
John C Lin
Jennifer R Stratton
Robert D Klein
Jaume Pons
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of BRPI0506793A publication Critical patent/BRPI0506793A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MéTODOS DE TRATAMENTO DA OBESIDADE OU DIABETES COM O USO DE NT-4/5. invenção refere-se a métodos para tratamento da obesidade, diabetes melito não insulino-dependente, síndrome metabólica e outras doenças relacionadas, por administração de um polipeptídeo NT-4/5. A invenção também se refere a composições farmacêuticas e kits compreendendo um polipeptídeo NT-4/5.
BRPI0506793-6A 2004-02-20 2005-02-22 métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5 BRPI0506793A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54639004P 2004-02-20 2004-02-20
PCT/US2005/005881 WO2005082401A1 (en) 2004-02-20 2005-02-22 Methods of treating obesity or diabetes using nt-4/5

Publications (1)

Publication Number Publication Date
BRPI0506793A true BRPI0506793A (pt) 2007-05-22

Family

ID=34910771

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506793-6A BRPI0506793A (pt) 2004-02-20 2005-02-22 métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5

Country Status (6)

Country Link
US (2) US20050209148A1 (pt)
EP (1) EP1720564A1 (pt)
JP (1) JP2007523196A (pt)
BR (1) BRPI0506793A (pt)
CA (1) CA2556923A1 (pt)
WO (1) WO2005082401A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007210862A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
WO2007095716A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011127304A2 (en) * 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
US12205686B2 (en) * 2020-02-27 2025-01-21 The Cleveland Clinic Foundation Identifying patients for intensive hyperglycemia management

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5364768A (en) * 1987-07-07 1994-11-15 Farmitalia Carlo Erba S.R.L. Process for the preparation of penems
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH03133378A (ja) * 1989-07-19 1991-06-06 Modrovich Ivan E 被験体を安定化させて液体中でのその生物学的活性を保存する方法
US6566091B1 (en) * 1990-09-25 2003-05-20 Genentech, Inc. Neurotrophic factor
US6506728B2 (en) * 1990-09-25 2003-01-14 Genentech, Inc. Methods using a novel neurotrophic factor, NT-4
CA2092567C (en) * 1990-09-25 2007-07-03 Arnon Rosenthal Nt-4 neurotrophic factor
ES2148144T3 (es) * 1990-11-20 2000-10-16 Dade Behring Marburg Gmbh Procedimiento para la estabilizacion de conjugados de enzima.
EP0666756B1 (en) * 1992-09-14 1999-11-24 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US20030191061A1 (en) * 1994-03-31 2003-10-09 Brewitt Barbara A. Treatment methods using homeopathic preparations of growth factors
US6024734A (en) * 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
WO1995031183A1 (en) * 1994-05-16 1995-11-23 Washington University Cell membrane fusion composition and method
MX9606598A (es) * 1994-06-24 1997-05-31 Behringwerke Ag Procedimiento para la estabilizacion de moleculas, o partes de moleculas, sensibles a la hidrolisis.
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
NZ333650A (en) * 1996-07-19 2000-02-28 Amgen Inc Analogs of cationic proteins like NT-3 (neurotrophin-3) and BDNF (brain derived neurotrophic factor) that are circulated more readily due to a lower isoelectric point and a lower protein charge relative to the native protein
AU729459B2 (en) * 1996-11-15 2001-02-01 Genentech Inc. Purification of neurotrophins
US6391312B1 (en) * 1997-01-23 2002-05-21 Sumitomo Pharmaceuticals Co., Limited Remedies for diabetes
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2300134A1 (en) * 1997-08-29 1999-03-04 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
EP1172113A4 (en) * 1999-04-16 2004-06-30 Sumitomo Pharma MEDICINE FOR AUTONOMOUS NEUROPATHIES
JP5249482B2 (ja) * 1999-06-16 2013-07-31 ボストン・バイオメデイカル・リサーチ・インステイテユート インビボのβ−アミロイドレベルの免疫学的制御
WO2001002376A1 (en) * 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated Amino-alkyl derivatives
EP1200440A1 (en) * 1999-07-06 2002-05-02 Vertex Pharmaceuticals Incorporated Quinuclidine derivatives for treatment of neurological disorders
JP2003503476A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド 環化アミド誘導体
JP2004510684A (ja) * 1999-07-06 2004-04-08 バーテックス　ファーマシューティカルズ　インコーポレイテッド 神経学的疾患の治療のためのアゾアミノ酸誘導体
WO2001002372A1 (en) * 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated Cyclized amino acid derivatives
EP1207882A4 (en) * 1999-07-30 2003-03-19 Vertex Pharma DERIVATIVES OF ACYCLIC AND CYCLIC AMINES
DE60002496T2 (de) * 1999-10-29 2004-03-25 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Verwendung von gdnf für behandlung von hornhautdefekten
US20030022840A1 (en) * 2000-02-18 2003-01-30 Michiko Kishino Drugs for ameliorating impaired glucose tolerance
EP1262189A1 (en) * 2000-03-06 2002-12-04 Sumitomo Pharmaceuticals Company, Limited Leptin-resistance ameliorating agents
CN1529599A (zh) * 2001-06-14 2004-09-15 ��̩��˹ҩ��ɷ����޹�˾ 可用于治疗神经元损伤的无环哌嗪和哌啶衍生物
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US6712086B1 (en) * 2002-12-20 2004-03-30 Sidney T. Fails Above ground meter box
AU2007210862A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist

Also Published As

Publication number Publication date
WO2005082401A1 (en) 2005-09-09
US20050209148A1 (en) 2005-09-22
US20090203610A1 (en) 2009-08-13
JP2007523196A (ja) 2007-08-16
EP1720564A1 (en) 2006-11-15
CA2556923A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
CL2006003672A1 (es) Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
WO2008055940A8 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
WO2004110375A3 (en) Combination therapy for the treatment of diabetes
CY1112398T1 (el) Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
BRPI0511703A (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o inìcio do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, sìndrome x, um distúrbio lipìdico, aterosclerose, e uma condição
CL2008002227A1 (es) Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad.
BRPI0519106A2 (pt) compostos, uso destes, processo para sua fabricaÇço, composiÇÕes farmacÊuticas, mÉtodo para o tratamento e/ou profilaxia de doenÇas que sço associadas com a dpp-iv
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
CL2010000375A1 (es) Compuestos mimeticos de glucocorticoides derivados de hidroxialquilo sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de un estado o trastorno seleccionado de diabetes tipo ii, obesidad, hipertension, entre otras (divisional de solicitud 585-03).
EA200802128A1 (ru) Новые нутрицевтические композиции
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0210383A (pt) compostos para o tratamento de distúrbios metabólicos
SE9702457D0 (sv) Screening
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
BRPI0516126A (pt) produtos farmacêuticos de polipeptìdeos intestinais vasoativos
BR0206847A (pt) Tratamento do diabete melito
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
AR075998A1 (es) Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
WO2006066747A8 (en) 4-aminopiperidine derivatives
BRPI0511367A (pt) uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6 ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.